LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | GSK1059615 | 10.0 | uM | LJP5 | 72 | hr | 1334 | 473 | 3970 | 0.1193 | -0.3266 |
| BT-20 | GSK1059615 | 10.0 | uM | LJP6 | 72 | hr | 1334 | 312 | 3970 | 0.0786 | -0.3879 |
| BT-20 | GSK1904529A | 10.0 | uM | LJP6 | 72 | hr | 1334 | 3781 | 3970 | 0.9523 | 0.9281 |
| BT-20 | Omipalisib | 10.0 | uM | LJP6 | 72 | hr | 1334 | 479 | 3970 | 0.1207 | -0.3245 |
| BT-20 | GSK 690693 | 10.0 | uM | LJP5 | 72 | hr | 1334 | 2183 | 3970 | 0.5498 | 0.3218 |
| BT-20 | GW843682X | 10.0 | uM | LJP6 | 72 | hr | 1334 | 648 | 3970 | 0.1633 | -0.2604 |
| BT-20 | HG-5-113-01 | 10.0 | uM | LJP5 | 72 | hr | 1334 | 780 | 3970 | 0.1966 | -0.2102 |
| BT-20 | HG-5-88-01 | 10.0 | uM | LJP6 | 72 | hr | 1334 | 2250 | 3970 | 0.5667 | 0.3473 |
| BT-20 | Imatinib | 10.0 | uM | LJP6 | 72 | hr | 1334 | 4052 | 3970 | 1.0205 | 1.0309 |
| BT-20 | JNK-9L | 10.0 | uM | LJP6 | 72 | hr | 1334 | 704 | 3970 | 0.1773 | -0.2392 |
| BT-20 | JW-7-24-1 | 10.0 | uM | LJP6 | 72 | hr | 1334 | 1493 | 3970 | 0.3762 | 0.0603 |
| BT-20 | Lapatinib | 10.0 | uM | LJP6 | 72 | hr | 1334 | 3645 | 3970 | 0.9181 | 0.8766 |
| BT-20 | LDN-193189 | 10.0 | uM | LJP5 | 72 | hr | 1334 | 515 | 3970 | 0.1297 | -0.3109 |
| BT-20 | Linifanib | 10.0 | uM | LJP6 | 72 | hr | 1334 | 3831 | 3970 | 0.9649 | 0.9471 |
| BT-20 | Linsitinib | 10.0 | uM | LJP5 | 72 | hr | 1334 | 3535 | 3970 | 0.8903 | 0.8348 |
| BT-20 | Mitoxantrone | 10.0 | uM | LJP5 | 72 | hr | 1334 | 382 | 3970 | 0.0963 | -0.3613 |
| BT-20 | Mitoxantrone | 10.0 | uM | LJP6 | 72 | hr | 1334 | 579 | 3970 | 0.1459 | -0.2865 |
| BT-20 | MK2206 | 10.0 | uM | LJP6 | 72 | hr | 1334 | 2201 | 3970 | 0.5544 | 0.3288 |
| BT-20 | Neratinib | 10.0 | uM | LJP5 | 72 | hr | 1334 | 2242 | 3970 | 0.5648 | 0.3444 |
| BT-20 | Nilotinib | 10.0 | uM | LJP5 | 72 | hr | 1334 | 1233 | 3970 | 0.3107 | -0.0383 |
| BT-20 | Nintedanib | 10.0 | uM | LJP6 | 72 | hr | 1334 | 2846 | 3970 | 0.7169 | 0.5735 |
| BT-20 | NU7441 | 10.0 | uM | LJP5 | 72 | hr | 1334 | 2375 | 3970 | 0.5982 | 0.3948 |
| BT-20 | Dactolisib | 10.0 | uM | LJP5 | 72 | hr | 1334 | 1437 | 3970 | 0.3621 | 0.0391 |
| BT-20 | NVP-TAE684 | 10.0 | uM | LJP6 | 72 | hr | 1334 | 2404 | 3970 | 0.6056 | 0.4059 |
| BT-20 | Palbociclib | 10.0 | uM | LJP6 | 72 | hr | 1334 | 1679 | 3970 | 0.4230 | 0.1309 |